RE:RE:Bottom I would have to say that Eve does not have first mover in Germany. Fortunitaly for them they do have those three contracts. Most players have boots in Germany, Australia, and other emerging markets.
Eve really needs to diversify themselves from the heard. Hexo is failing majorly because they took a major focus and built the company as a recreational player. They have very few active medical patients. If you look at their ER the average sale price per gram doubles on the medical side. Medical is a constant stream as patients have monthly persciptions.
Aphria has done so well from their purchase of the distribution company in EU I believe. Otherwise I dont think they would be holding up so well. ACB is just lost trying to figure out why the fk they build out massive facilities without having a surefire pipeline for sales. They won the Italian contract by underbidding companies by over 50% to the nearest compeditor. Its a relatively small contract, but they royally fkt the industry by shaving their margins and setting the bar so low.
I think if 2,0 doesnt save some of these companies we'll see some of the big players fold as well as the little ones. ACB and Hexo namely. Not only that, but HEXO's institutional investor and JV parter just announced laying off 500 jobs globally and renaming to Molson Coors Beverages, rather than Brewing. Citing that millenials are moving away from beer. Lets hope that move is to cannabis.
Bottom line is that this company really needs to step up and provide an operational update. Maybe some guidance. Our last earnings numbers are bad, and they really need to show some growth, be in in guidance or reality.